Holding(s) in Company

Summary by AI BETAClose X

Physiomics plc announced that Robert McFadden now holds 13,678,940 ordinary shares, representing 3.02% of the company's issued share capital, following a market purchase on August 18, 2026, at 0.47 pence per share. This direct interest signifies a notable stake in the mathematical modelling and data science company.

Disclaimer*

Physiomics PLC
21 August 2026
 

Physiomics | Physiomics - Model Informed Drug Development - Pharmacometrics, Quantitative System Pharmacology and Biostatistics Consulting
21 August 2026

 

Physiomics plc

 

("Physiomics" or the "Company")

 

Holding in Company

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that it was notified on 20 August 2026 by Robert McFadden that as of 18 August 2026 he holds 13,678,940 ordinary shares of 0.4 pence each in the Company representing 3.02% of the Company's issued share capital, following a market purchase at 0.47 pence per share. The interest is held directly.

 

ENDS

 

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

 

Enquiries:

Physiomics plc

Mike Whitlow

 

Email:  info@physiomics.co.uk

Strand Hanson Ltd (NOMAD and Broker)

James Dance & James Bellman

Tel:  +44 (0) 20 7409 3494

 

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Physiomics (PYC)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today